D1AMOND Study for Tourette's Syndrome
Study Overview
Study directors: Elysa Marco, MD and Kevin Shapiro, MD
Recruiting: Yes
Study title: Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults
Conditions: Tourette’s Syndrome/Tourette’s Disorder and tics
Purpose: The purpose of this study is to find out whether ecopipam, a selective dopamine blocker, reduces tics in individuals with Tourette’s Syndrome.
Eligibility
Inclusion criteria:
Above 6 years old
Diagnosed (or suspected) Tourette’s Syndrome
Moderate-to-severe tics
Exclusion criteria:
History of seizures
Unable to swallow tablets
Unstable medical or psychiatric illness
Currently using certain medications to reduce tics – contact our study team to discuss
What is Involved?
Testing: Comprehensive tic assessments, psychiatric questionnaires, and medical evaluations
Frequency of visits: Once a month for three months, followed by weekly/biweekly assessments for an additional three months if medication is effective in reducing tics
Costs: No costs will be charged for any of the study procedures. We are also able to support with Lyfts or reimburse for mileage to and from visits
Payment: In return for the time, effort, and travel expenses, adults will be compensated $100 per visit and children with their caregivers will be compensated $175 per visit
Location and Contact Information
Location: Cortica Glendale and Cortica Marin
Coordinator: Kelly Olvany – kolvany@corticacare.com – (331) 272-1322
Fill out our Interest Form and we will contact you!
